Syngene reports FY26 revenue of Rs 3,739 Cr, up 3%; Q4 revenue at Rs 1,037 Cr

Steady growth led by biologics and CRDMO business, EBITDA margin at 25% with continued investments in ADCs, peptides, and digital capabilities

Granules India Q4FY26 revenue jumps 23% to Rs 14,706 million; FY26 revenue at Rs 53,656 million

The figures highlight double-digit revenue growth, margin expansion, and continued momentum in complex generics and peptides CDMO platform

OneSource Pharma, Dr Reddy’s secure Health Canada nod for generic Semaglutide

Approval for generic Semaglutide Injection strengthens CDMO partnership, enabling scalable supply from OneSource’s US FDA-approved Bengaluru facility

Aurigene bets big on CRDMO expansion with $100 million outlay

Deploys $40 million in Hyderabad; advances APIs, peptides, and global small molecule capabilities

Croda unveils next-gen Matrixyl Neolide to redefine long-lasting skincare performance

The move reinforces Croda’s push to fuel growth through high-impact innovation across its Consumer Care portfolio

Asahi Kasei pushes into human trials with new autoimmune drug candidate

The study is being conducted through its Japan-based pharmaceutical arm, Asahi Kasei Therapeutics Corp

Strengthening India’s pharma brand through compliance-first manufacturing: Vijay Kumar Aggarwal, MD, Medicef Pharma

By prioritising absolute compliance, leveraging the power of digital tools, and aligning with government policies, the sector is locking in its future leadership

Orbicular's partner secures tentative U.S. ANDA approval for a generic version of Ozempic

OneSource is the contract development and manufacturing organization (CDMO) partner for this product

Galderma rolls out next-generation regenerating skin nectar

Aurigene, Alveus advance obesity pipeline with ALV-200 candidate nomination

The collaboration combines Alveus’ expertise in metabolic biology and therapeutic strategy with Aurigene’s integrated discovery capabilities